Hepatic fibrosis. Hepatic fibrosis
Conditions
Interventions
Intervention 1: control group: no treatment. Intervention 2: Intervention group 1: Deferoxamine 10-20 mg/kg. Frequency and route of administration is once per day contineous IV infusion over 8 hours.
Treatment - Drugs
Intervention group 1: Deferoxamine 10-20 mg/kg. Frequency and route of administration is once per day contineous IV infusion over 8 hours.
Sponsors
Vice chancellor of research, Shiaz Univeisity of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: signing informed consent; male or female aged between 2-18 years at screening; new pediatric cancer patients who are going to receive Anthracyclin drugs as part of their chemotherapy regimen. Exclusion criteria: patients below two years old; patients with previous history of treatment with any kind of chemotherapy or radiotherapy; diagnosis of primary or metastatatic hepatic tumors, chronic liver disease and liver cirrhosis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function test. Timepoint: before and after chemotherapy coarse. Method of measurement: hematology analysis.;Hyaluronic acid. Timepoint: before and after chemotherapy coarse. Method of measurement: FDM analysis kit.;Gamma-microglobulin. Timepoint: before and after chemotherapy coarse. Method of measurement: hematology analysis.;Liver fibrosis. Timepoint: before and after chemotherapy coarse. Method of measurement: liver fibroscan.;Liver dysfunction signs. Timepoint: before and after chemotherapy coarse. Method of measurement: Sonograghy. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Bordbar
Shiraz University of Medical Sciences
Outcome results
None listed